丹参及川芎嗪注射液联合西药治疗早发型重度子痫前期临床研究

Study on Treatment of Eearly Onset of Severe Pre-eclampsia by Salviae Injection and Ligustazine Injection in Combining with Western Medicine

目的观察丹参及川芎嗪注射液联合西药在早发型重度子痫前期治疗中的作用及妊娠结局。方法采用开放前瞻病例对照研究，对63例早发型重度子痫前期（孕29～32周）患者，按入院顺序分为联合组和对照组，对照组31例采用西医治疗方案，联合组32例在西医治疗基础上加用丹参注射液及盐酸川芎嗪注射液，分析两组治疗前后血浆黏度、D-二聚体变化及妊娠结局。结果联合组延长孕周优于对照组[（11．0±1．2）天US（6．0±1．5）天]；胎儿窘迫发生（11例）少于对照组（16例）；新生儿死亡（4例）少于对照组（8例）；以上两组比较，均P〈0．05。联合组治疗后血浆黏度比值（1．20±0．13）低于治疗前（2．29±0．13，P〈0．05）；治疗后D-二聚体为（1．61±0．45）mg／L，低于治疗前的（2．40±0．09）mg／L（P〈0．05）；对照组治疗前后比较差异均无统计学意义。结论联合应用丹参及川芎嗪注射液治疗早发型重度子痫前期，可改善血液的高凝状态，延长孕周，改善围产结局，降低孕妇并发症发生及新生儿死亡率。

Objective To evaluate the efficacy of Salviae injection and ligustrazine injection （S ＆ L） in combining with Western medicine for treatment of early onset of severe pre-eclampsia （ EOSP）, and its impact on pregnancy. Methods An open prospective controlled study was conducted on 63 women suffering from EOSP during the 29th-32th week of pregnancy. They were assigned, according to the sequence of hospitalizing, to the treated group （32 cases） and the control group （31 cases）. Both groups were treated with conventional Western medical treatment, but S ＆ L were administered additionally to the treated group. Levels of plasma D-dimer, blood viscosity, and outcome of the pregnancy were analyzed. Results The effect in prolonging the pregnancy and lowing the incidence of fetal distress and newborn death in the treated group was superior to that in the control group, the corresponding data were 11.0 ± 1.2 days, 11 cases, 4 cases in the treated group and 6.0 ± 1.5 days, 16 cases and 8 cases in the control group, respectively. Levels of blood viscosity ratio and D-dimer in the treated group were lowered significantly after treatment （1.20 ±0. 13 vs 2.29 ±0. 13,1.61 ±0.45 mg/L vs 2.40±0.09 mg/L）, which had no remarkable change in the control group. Conclusion Combined application of S ＆ L for treatment of EOSP could improve the blood hyperviscosity, prolong the pregnancy week, and improve the outcome of pregnancy to reduce incidence of perinatal morbidity and mortality in patients.